Clinical Trials Browser

Active not recruiting × Has results × Everolimus × Clear all

NCT03049189 2026-04-06

COMPETE

Phase 3 Active not recruiting

324 enrolled 15 charts

Neuroendocrine Tumors

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 2 FDA

Carcinoma, Renal Cell

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Phase 2 Active not recruiting

35 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell

NCT01674140 2026-02-10

e3

Phase 3 Active not recruiting

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01068249 2025-11-18

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

42 enrolled 11 charts

Recurrence, Endometrial Neoplasms

NCT03032406 2025-07-22

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Phase 2 Active not recruiting

53 enrolled 12 charts

Breast Neoplasms

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3 Active not recruiting

755 enrolled 28 charts 2 FDA

Carcinoma, Renal Cell, Kidney Neoplasms